Rational Pharmacotherapy in Cardiology

Scope & Guideline

Exploring the Synergy of Cardiology and Rational Drug Use

Introduction

Welcome to the Rational Pharmacotherapy in Cardiology information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Rational Pharmacotherapy in Cardiology, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageMulti-Language
ISSN1819-6446
PublisherSOC CARDIOLOGY RUSSIAN FEDERAT
Support Open AccessYes
CountryRussian Federation
TypeJournal
Convergefrom 2012 to 2024
AbbreviationRATION PHARMACOTHER / Ration. Pharmacother. Cardiol.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPETROVERIGSKII PEREULOK 10, MOSCOW 101990, RUSSIA

Aims and Scopes

The journal 'Rational Pharmacotherapy in Cardiology' primarily focuses on the intersection of pharmacotherapy and cardiovascular diseases, emphasizing evidence-based practices and innovative treatment strategies. It aims to provide insights into the pharmacological management of various cardiac conditions, while also addressing the complexities of comorbidities and patient adherence.
  1. Pharmacotherapy in Cardiovascular Diseases:
    The journal publishes extensive research on the pharmacological management of cardiovascular diseases, including studies on the efficacy and safety of various drug therapies, including anticoagulants, antihypertensives, and lipid-lowering agents.
  2. Comorbidities and Cardiovascular Health:
    A significant focus is placed on the management of cardiovascular diseases in the context of comorbid conditions such as diabetes, chronic kidney disease, and obesity, exploring how these factors influence treatment outcomes.
  3. Clinical Outcomes and Prognostic Factors:
    Research often emphasizes the prognostic significance of various clinical factors, laboratory markers, and biomarkers in predicting outcomes for patients with cardiovascular diseases, thereby aiding in risk stratification and personalized medicine.
  4. Innovative Therapeutic Approaches:
    The journal highlights novel treatment strategies, including the use of new drug classes, combination therapies, and personalized medicine approaches, while also addressing adherence to therapy and patient-centered care.
  5. Epidemiological and Observational Studies:
    There is a strong emphasis on epidemiological studies that investigate the prevalence and impact of cardiovascular diseases, treatment patterns, and adherence among diverse populations.
The journal has seen a rise in interest in several emerging themes, reflecting current trends and advancements in cardiology and pharmacotherapy. These themes highlight the dynamic nature of research in this field.
  1. Pharmacogenomics and Personalized Medicine:
    Recent publications emphasize the role of genetic factors in drug response, particularly in anticoagulant therapy, indicating a growing interest in personalized medicine tailored to individual patient profiles.
  2. Impact of COVID-19 on Cardiovascular Health:
    There is an increased focus on the cardiovascular implications of COVID-19, including its effects on existing heart conditions and the management of patients post-infection.
  3. Integrative Approaches to Cardiovascular Care:
    Studies exploring integrative and multidisciplinary approaches to cardiovascular care are on the rise, highlighting the importance of collaboration among specialists in managing complex patient cases.
  4. Chronic Disease Management and Patient Adherence:
    Research focusing on adherence to treatment regimens, particularly in the context of chronic diseases, is increasingly relevant as it impacts overall treatment effectiveness and patient outcomes.
  5. Innovative Biomarkers and Diagnostic Tools:
    The journal is publishing more studies examining novel biomarkers and diagnostic techniques that enhance the understanding and management of cardiovascular diseases.

Declining or Waning

While the journal continues to thrive in many areas, certain themes appear to be waning, reflecting shifts in research priorities and clinical practice. These declining scopes indicate a need for adaptation in focus areas.
  1. Traditional Antiarrhythmic Therapies:
    Research on classic antiarrhythmic drugs has seen a decrease, possibly due to the emergence of newer therapies and a shift towards more personalized approaches in managing arrhythmias.
  2. Generalized Lipid Management Strategies:
    There is a noticeable decline in studies focused on traditional lipid management protocols, as more emphasis is placed on innovative therapies like PCSK9 inhibitors and inclisiran.
  3. Single-Disease Focus Studies:
    Research focusing solely on single cardiovascular diseases without considering comorbidities is becoming less frequent, as the field increasingly recognizes the importance of a multimorbid perspective.

Similar Journals

American Journal of Cardiovascular Drugs

Unveiling Breakthroughs in Cardiovascular Medicine
Publisher: ADIS INT LTDISSN: 1175-3277Frequency: 6 issues/year

American Journal of Cardiovascular Drugs, published by ADIS INT LTD, is a premier peer-reviewed journal dedicated to the field of cardiology and cardiovascular medicine. With an ISSN of 1175-3277 and an E-ISSN of 1179-187X, this esteemed journal has established itself as a crucial platform for disseminating high-quality research since its inception in 2001. It holds a significant position in its domain, ranking in the second quartile (Q2) across several categories including Cardiology, Medicine (miscellaneous), and Pharmacology (medical) for the year 2023. With its Scopus ranks placing it in the 81st percentile for Cardiology and 77th percentile for Pharmacology, the journal is highly regarded among professionals, researchers, and students alike. While it is not an open-access journal, its comprehensive articles and systematic reviews provide an in-depth exploration of cardiovascular drug therapy, therapeutic advancements, and clinical practices, making it an invaluable resource for anyone invested in the future of cardiovascular health.

International Journal of Cardiology

Leading the Charge in Heart Health Innovations
Publisher: ELSEVIER IRELAND LTDISSN: 0167-5273Frequency: 24 issues/year

The International Journal of Cardiology is a premier publication in the field of Cardiology and Cardiovascular Medicine, published by Elsevier Ireland Ltd. With an impressive impact factor and ranked in the top quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and scholars committed to advancing cardiovascular health. Founded in 1981, the journal has been pivotal in disseminating significant findings, with a wide-ranging scope that includes original research, reviews, and clinical studies aimed at improving patient outcomes and understanding heart diseases. Its robust ranking of #73 out of 387 in Scopus ensures that it remains a leading platform for impactful cardiovascular research. While currently not an open-access publication, the journal's commitment to quality and relevance makes it an essential reference point within an ever-evolving medical landscape. For those engaged in cardiovascular research, the International Journal of Cardiology is not just a journal; it's an indispensable source of knowledge shaping the future of heart health.

VASCULAR PHARMACOLOGY

Exploring the frontiers of vascular pharmacotherapy.
Publisher: ELSEVIER SCIENCE INCISSN: 1537-1891Frequency: 12 issues/year

Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.

Journal of the Practice of Cardiovascular Sciences

Elevating Standards in Cardiovascular Research and Practice
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2395-5414Frequency: 3 issues/year

Journal of the Practice of Cardiovascular Sciences, published by Wolters Kluwer Medknow Publications, is an esteemed Open Access journal dedicated to advancing knowledge in the field of cardiovascular health. With its ISSN 2395-5414 and E-ISSN 2454-2830, the journal serves as a vital platform for researchers, healthcare professionals, and students to disseminate and access high-quality studies, innovations, and practical applications related to cardiovascular sciences. Established in 2015 as an Open Access journal, it promotes widespread sharing of insights to enhance cardiovascular practices and address contemporary challenges in the field. As part of a reputable publishing group, the journal is poised for growth and impact, contributing significantly to the ongoing dialogue in cardiovascular research and clinical practice.

Revista de la Federacion Argentina de Cardiologia

Advancing cardiovascular knowledge for a healthier tomorrow.
Publisher: FEDERACION ARGENTINA CARDIOLOGIAISSN: 0326-646XFrequency: 4 issues/year

Revista de la Federacion Argentina de Cardiologia is a vital publication in the field of Cardiology and Cardiovascular Medicine, providing a platform for researchers and healthcare professionals to share significant findings and innovative concepts since its inception in 2012. Published by the Federacion Argentina Cardiology, this journal specifically addresses contemporary issues and advancements within cardiology, contributing to the scholarly dialogue essential for improving cardiovascular health. Despite being categorized in the Q4 quartile for 2023 and presently ranking #358 out of 387 in its field, the journal remains committed to fostering academic inquiry and disseminating valuable research for both local and global audiences. Although it is not an open-access journal, it strives to balance accessibility with rigorous academic standards, ensuring quality contributions that are critical for practitioners and students alike. The journal’s ongoing evaluation and adaptation in the ever-evolving landscape of cardiology underscore its importance in advancing cardiovascular science and practice.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Leading the way in cardiovascular pharmacological research.
Publisher: SAGE PUBLICATIONS INCISSN: 1074-2484Frequency: 6 issues/year

The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.

Cardiovascular Endocrinology & Metabolism

Connecting the Dots Between Endocrine Function and Heart Health
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2574-0954Frequency: 4 issues/year

Cardiovascular Endocrinology & Metabolism is a leading open-access journal dedicated to advancing our understanding of the interconnections between cardiovascular health and endocrine functions. Published by Lippincott Williams & Wilkins, this journal serves as a vital resource for researchers and clinicians alike, providing timely insights into the intricate relationships between metabolic disorders and cardiovascular diseases. With an impressive impact factor and categorized in Q2 for both Cardiology and Cardiovascular Medicine as well as Endocrinology, Diabetes, and Metabolism, it holds a significant position within its respective fields. The journal has been fully open access since its inception in 2012, ensuring that critical research is accessible to a global audience. By fostering innovation and collaboration, Cardiovascular Endocrinology & Metabolism aims to promote better health outcomes and stimulate novel research directions, making it an essential resource for professionals striving to bridge the gaps between these two critical domains.

Cardiology Journal

Advancing cardiovascular knowledge without barriers.
Publisher: VIA MEDICAISSN: 1897-5593Frequency: 6 issues/year

Cardiology Journal, published by VIA MEDICA, stands as a prominent resource in the field of cardiology and cardiovascular medicine, with an ISSN of 1897-5593 and an E-ISSN of 1898-018X. Recognized for its Open Access model established since 1994, this journal facilitates widespread dissemination of critical research findings, allowing practitioners and researchers globally to access valuable insights without barriers. Based in Poland, with an address at UL SWIETOKRZYSKA 73, 80-180 GDANSK, it has achieved a respectable Q2 classification in 2023 for both Cardiology and Miscellaneous Medicine categories, reflecting its influence and quality within the scholarly community. With a Scopus ranking placing it at #117 out of 387 in Cardiology, it lies within the 69th percentile, underpinning its commitment to advancing knowledge in cardiovascular health. The journal’s converged years extending from 2006 to 2024 ensure it captures ongoing developments in a rapidly evolving field. As such, the Cardiology Journal serves as an indispensable platform for researchers, professionals, and students dedicated to exploring the frontiers of cardiac science and improving patient care.

PROGRESS IN CARDIOVASCULAR DISEASES

Transforming Knowledge into Clinical Practice
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 0033-0620Frequency: 6 issues/year

PROGRESS IN CARDIOVASCULAR DISEASES is a leading journal in the field of cardiology and cardiovascular medicine, published by W B SAUNDERS CO-ELSEVIER INC. With an impressive impact factor that places it in the esteemed Q1 quartile of its category, this journal ranks among the top 32 out of 387 journals in its field, positioning itself in the 91st percentile. Since its inception in 1958 and continuing until 2024, it has been a prolific source of cutting-edge research, reviews, and clinical insights that contribute significantly to the understanding and treatment of cardiovascular diseases. Although it does not currently offer open access options, the journal's rigorous peer-review process ensures that all published content meets the highest standards of scientific excellence. As a key resource for researchers, practitioners, and students alike, PROGRESS IN CARDIOVASCULAR DISEASES serves as an indispensable tool for advancing knowledge and practice in cardiovascular health.

Heart Views

Empowering heart health through open access research.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1995-705XFrequency: 4 issues/year

Heart Views is a prestigious and influential journal dedicated to the field of cardiology and cardiovascular medicine, published by Wolters Kluwer Medknow Publications. With an Open Access model implemented since 2010, the journal ensures that its valuable research findings are accessible to a global audience, fostering knowledge dissemination and collaboration among researchers, professionals, and students alike. While the current impact factor is not specified, its commitment to quality and peer-reviewed content has established it as a significant resource within the cardiology community. The journal publishes a diverse array of articles, including original research, reviews, and clinical studies aimed at advancing the understanding and treatment of cardiovascular diseases. Heart Views serves as an essential platform for sharing innovative ideas and practices, thereby contributing to improved patient care and outcomes in the dynamic field of heart health.